Shearman & Sterling advised the underwriters of Cytek Biosciences’ initial public offering of 16,749,330 shares of common stock at a public offering price of $17.00 per share, resulting in gross proceeds to the company of approximately $237 million, before deducting underwriting discounts and commissions and offering expenses. The offering consisted of 13,949,401 shares sold by Cytek and 2,799,929 shares sold by certain of its stockholders. The shares began trading on The Nasdaq Global Select Market under the ticker symbol “CTKB” on July 23, 2021.
Morgan Stanley, Goldman Sachs & Co., Piper Sandler and Cowen acted as joint book-running managers for this offering.
Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek Biosciences’ novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek Biosciences’ FSP platform includes its core instruments, the Aurora and Northern Lights systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers.